Universal donor cells

Details Universal donor cells Universal donor cells

2005-07-12

2005-07-12

Wehbé, Anne M. (Department: 1632)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S320100, C435S455000, C800S008000, C800S013000, C800S018000, C514S04400A

Reexamination Certificate

active

06916654

ABSTRACT:
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.

REFERENCES:
patent: 4873191 (1989-10-01), Wagner
patent: 4883755 (1989-11-01), Carabasi et al.
patent: 5336615 (1994-08-01), Bell et al.
patent: 5416260 (1995-05-01), Koller et al.
patent: 6100443 (2000-08-01), Sims
patent: 91/01140 (1991-02-01), None
patent: 91/05855 (1991-05-01), None
Houdebine, Production of pharmaceutical proteins from transgenic animals, 1994, Journal of Biotechnology, vol. 34 pp. 269-287.
Greiner et al., SCID mouse models of human stem cell engraftment, 1998, Stem Cells, vol. 16 pp. 166-177.
Bradley et al., Modifying the mouse: design and desire, 1992, Bio/Technology, vol. 10 pp. 534-539.
Adams, et al., “Contribution of the repeating domains of membrane cofactor (CD46) of the complement system to ligand binding and cofactor activity,”J. Immunol.147:3005-3011 (1991).
Adorini, et al., “In vivo competition between self peptides and foreign antigens in T-cell activation,”Nature334:623-28 (1988).
Ausubel, et al., “In situ hybridization and immunohistochemistry,”Curr. Protocols in Molecular Biology2:14.5.5, 14.6.1-14.6.13 (1989).
Bell, et al., “The reconstitution of living skin,”J. Invest. Derm.81:2s-10s (1982).
Bikoff, et al., “Defective major histomcompatibility complex class II assembly, transport, peptide acquisition, and CD4 T Cell selection in mice lacking invariant chain expression,”J. Exper. Med.177:1699-1712 (1993).
Bix, et al., “Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice,”Nature349:329-331 (1991).
Bradley, “Production and analysis of chimeric mice,” inTeratocarcinomas and Embryonic Stem Cells: A Practical Approachpp. 113-151 (IRL Press: Oxford-Washington, D.C., 1987).
Brasile, et al., “A probable mechanism for allograft rejection in HLA-identical combinations,”Trans. Proceed.19:894-95 (1987).
Brasile, et al., “Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation,”Transplantation40:672-675 (1985).
Brinster, et al., “Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs,”Proc. Natl. Acad. Sci. USA82:4438-442 (1985).
Brostoff & Mason, “Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells,”J. Immunol.133:1938-42 (1984).
Cheng, et al., “Fluorescence resonance energy transfer study of the associative state of membane-bound complexes of complement proteins C5b-8,”J. Immunol.135:459-464 (1985).
Coyne, et al., “Mapping epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor,”J. Immunol.149:2906-13 (1992).
Culliton, “Designing cells to deliver drugs,”Science246:746-751 (1989).
Dalmasso, et al., “Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients,”Am. J. Pathol.140(5):1157-66 (1992).
Daniels, “Cromer-related antigens-blood group determinanats on decay-accelerating factor,”Vox. Sang.56:205-211 (1989).
Doetschman, “The in vitro development of blastocyst-derived embryonic stem cells:formation of visceral yolk sac, blood islands and myocardium,”J. Embryol. Exp. Morph.87:27-45 (1985).
Dordrecht, Medical progress through technology 115-163 (1989).
Fischel, et al., “Prolonged survival of a discordant cardiac xenograft in a rhesus monkey,”Transplant Proc.23(1 Pt 1):589-90 (1991).
Freshney, “A dimensional culture systems,”Culture of Animal Cells-A manual of basic techniques,Chap. 22, pp. 297-307, A.R. Liss, Inc.:New York, 1987.
Goetz, et al., “Long-term serial cultivation of arterial and capillary endothelium for adult bovine brain,”In Vitro Cell Dev. Biol.21:172-180 (1985).
Grusby, et al., “Depletion of CD4+ Tcells in major histocompatibility complex class II-deficient mice,”Science253:1417-20 (1991).
Gullino & Knazek, “Tissue culture on artificial capillaires,”Methods Enzymol.58:178-184 (1979).
Haisch, et al., “The vascular endothelial cell is central to xenogeneic immune reactivity,”Surgery108:306-311 (1990).
Hamilton & Sims, “The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-1 and A-II to human endothelial cells,”J. Clin. Invest.88:1833-1840 (1991).
Hamilton, et al., “Regulatory control of the terminal complement proteins at the surface of human endothelial cells: Neutralization of a C5b-9,”Blood76:2572-2577 (1990).
Hansbrough, et al., “Expression of a liver fatty acid binding protein/human decay-accelerating factor/HLA-B44 chimeric gene in transgenic mice,”Am. J. Physiol.260:929-39 (1991).
Hantzopoulos, et al., “Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector,”Proc. Natl. Acad. Sci. USA86:3519-23 (1989).
Hattori, et al., “Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial Von Willebrand Factor and translocation of granule membrane protein GMP-140 to the cell surface,”J. Biol. Chem.264:9053-60 (1989).
Hilbert, et al., “Tissue-derived biomaterials and their use in cardiovascular prosthetic devices,”Med. Progress Through Technology14:115-163 (1989).
Hogan, et al.,Manipulating the mouse embryo, A laboratory manualCold Spring Harbor Laboratory, 1986.
Holguin, et al., “Analysis of the effects of activation of the alternate pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor,”J. Immunol.148:498-502 (1992).
Houdebine, “Production of Pharmaceutical proteins from transgenic animals,”J. Biotech.34:269-87 (1994).
Kohn, et al., “Retroviral-mediated gene transfer into mammalian cells,”Blood Cell13:285-298 (1987).
Koller, et al., “Normal development of mice deficient in β2M. MHC class I proteins, and CD8+T cells,”Science248:1227-30 (1990).
Krych, et al., “Sites within the complement C3b/C4b receptor important for the specificity of ligand binding,”Proc. Natl. Acad. Sci. USA88:4353-57 (1991).
Lider, et al., “Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis,”Science239:181-3 (1988).
Lublin, et al., “Decay-accelerating factor: biochemistry, molecular biology, and function,”Annu. Rev. Immunol.7:35-58 (1989).
Lublin, et al., “The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1,”J. Exp. Med.165:1731-36 (1987).
Madri, et al., “The collagenous components of the subendothelium. Correlation of structure and function,”Lab. Invest.43(4):303-15 (1980).
Madri & Williams, “Capillary endothelial cell cultures: phenotypic modulation by matrix components,”J. Cell. Biol.97(1):153-65 (1983).
Madri, et al., “Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix,”J. Cell. Biol.

Affiliated with

Also associated with

Rating

Universal donor cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Universal donor cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Universal donor cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3383608